Abstract:Background:Although cigarette smoking is a risk factor for multiple disorders, it has long been thought to protect against Parkinson's disease (PD). Quantitative susceptibility mapping (QSM) is a novel magnetic resonance imaging (MRI)-based technique for assessing iron accumulation in vivo that has been widely applied in PD studies. This study aimed to investigate how cigarette smoking affects clinical performance of PD using quantified iron deposition as a proxy for PD pathology.Methods:In this observational study, we enrolled 35 male PD patients and 47 male healthy controls (HCs) and divided them into four groups. We performed an enhanced T2 star-weighted angiography (ESWAN) MRI sequence to measure the iron content of the nuclei within the nigrostriatal pathway. With the age and total intracranial volume (TIV) controlled as covariates, we performed inter-group comparisons of QSM values and moderation analyses for PD patients using smoking status and the smoking index (SI), respectively, as moderator variables.Results:The 2-way multivariate analysis of covariance (MANCOVA) results showed higher QSM values in the left red nucleus (P=0.024) in PD patients compared with those in HCs, and in the bilateral globi pallidi [left/right (L/R): P=0.009/0.003], substantia nigra pars compacta (SNc; L/R: P=0.001/0.037), and right substantia nigra pars reticulata (SNr; P=0.002) in non-smokers compared with smokers, with no marked interaction effect between PD and smoking status observed when applying the Bonferroni adjustment for multiple comparisons. Using cigarette smoking status and the SI as separate moderator variables, the moderation was shown up by a significant interaction effect in a disordinal and double-edged form. In our results, smoking-moderated protection for PD movement deficits emerged when PD was progressed. Among the affected deep brain nuclei, the nuclei most moderated by the impact of cigarette smoking on the interaction between brain iron and PD symptoms were the thalamus [smoking status associated with the Unified Parkinson's Disease Rating Scale (UPDRS) total score, P=0.04 (L); rigidity, P=0.03 (L); SI associated with UPDRS-III, P (L/R) =0.049/0.0497; rigidity, P (L/R) =0.01/0.02; bradykinesia, P (L/R) =0.048/0.04], the right red nucleus (SI associated with rigidity, P=0.04; bradykinesia, P=0.02), and the left SNc [smoking status associated with the Hoehn and Yahr (H&Y) stage, P=0.01].Conclusions:This was the first study investigating the impacts of current cigarette smoking on PD using quantified iron deposition. Our study confirmed the protective role of cigarette smoking against PD, consistent with the findings of previous studies. Furthermore, neuroprotection was present only when the PD pathology had progressed to a certain extent. In the interaction between iron deposition and clinical PD symptoms, our findings suggest that the thalamus, red nucleus, and SNc are likely to be the most affected nuclei moderated by cigarette smoking.

Integrating Mendelian Randomization with Single-cell Sequencing Data Reveals the Causal Effect and Related Mechanisms of Smoking on Parkinson's Disease

Neural Substrates for the Association Between Cigarette Smoking and Parkinson's Disease

Association between cigarette smoking and Parkinson's disease: a neuroimaging study

The Protective Role of Cigarette Smoking Against Parkinson’s Disease Via Moderation of the Interaction Between Iron Deposition in the Nigrostriatal Pathway and Clinical Symptoms

Genetic correlation and causality between smoking and 42 neuropsychiatric and gastrointestinal diseases

Smoking and coronary artery disease risk in patients with diabetes: A Mendelian randomization study

Exploring the Cross-Cancer Effect of Smoking and Its Fingerprints in Blood DNA Methylation on Multiple Cancers: A Mendelian Randomization Study

Cigarette Smoking and Schizophrenia: Mendelian Randomisation Study.

Mendelian randomization analysis provides causality of smoking on the expression of ACE2, a putative SARS-CoV-2 receptor

Clearing the Smoke: What Protects Smokers from Parkinson's Disease?

Genome-wide Association Studies for Identifying Genetic Architecture of SGRQ in Smoking Population

Smoking and heart failure: a Mendelian randomization and mediation analysis

Exploring the Nicotine-Parkinson's disease link - Insights from the UK Biobank

Neurogenetic underpinnings of nicotine use severity: Integrating the brain transcriptomes and GWAS variants via network approaches

Appraising the causal role of smoking in multiple diseases: A systematic review and meta-analysis of Mendelian randomization studies

An Exploratory Analysis on Gene-Environment Interactions for Parkinson Disease (PD4.003)

The causal nexus between diverse smoking statuses, potential therapeutic targets, and NSCLC: insights from Mendelian randomization and mediation analysis

Identification of Novel Proteins Mediating Causal Association Between Smoking and Essential Hypertension: A Mendelian Randomization Study

Mendelian randomization analyses of smoking and Alzheimer's disease in Chinese and Japanese populations

Genetic correlation between smoking behavior and gastroesophageal reflux disease: insights from integrative multi-omics data

Smoking behaviors, physical activities, pulmonary diseases and COVID-19 severity: A Mendelian randomization study